Dr. Newton’s unique background, featuring specialized AI certifications in both healthcare and business, allows him to bridge the gap between complex technology and real-world professional application...

Technology for Neuropathy

Teaching Opioid Alternatives

Breast Cancer & Med Cannabis (Basic)

Breast Cancer & Med Cannabis (Advanced)

Live Class: Trading with AI

FUTURES ... 2nd Sunday | ORL Cars & Coffee

if (t < 93000) return DayRegime.PreMarket;

if (t < 95000) return DayRegime.OpeningDrive;

if (t < 110000) return DayRegime.MidMorningTrend;

if (t < 120000) return DayRegime.LateMorning;

if (t < 133000) return DayRegime.Lunch;

if (t < 143000) return DayRegime.EarlyAfternoon;

if (t < 154500) return DayRegime.PowerHour;
Below is a professional breakdown of the U.S. index futures trading day (e.g., YM / ES) segmented by time, behavior, and dominant pattern tendencies.This assumes regular U.S. equity session (RTH): 9:30 AM – 4:00 PM ET.
I. Pre-Market Structure (6:00 – 9:29 AM ET)1️⃣ Early Pre-Market (6:00 – 8:20)Character:Thin liquidityOvernight inventory positioningGlobex range developmentCommon Patterns:Range buildingOvernight high/low testsVWAP reversionFalse breakouts due to thin liquidityEdge Type:Mean reversionOvernight structure plays
2️⃣ News Window (8:30 – 9:15)(Economic releases: CPI, NFP, GDP, etc.)Character:Sudden volatility expansionLiquidity vacuum movesRapid repricingCommon Patterns:News spike & retraceNews spike & continuationLiquidity grab through overnight high/lowEdge Type:Fade the spike (if rejection)Acceptance breakout if volume confirms
II. Opening Drive Phase (9:30 – ~9:50)This is the most structurally important part of the day.1️⃣ Opening Drive (OD)Time: 9:30–9:40 (sometimes extends to 9:50)Character:Institutional imbalanceLarge program ordersHigh volatilityWide range candlesPatterns Seen:Straight-line impulse moveGap-and-goOpening trend continuationOpening range breakout (ORB)Stop-run through overnight high/lowSubtypes:Drive & HoldDrive & PullbackDrive & ReverseEdge Type:Momentum breakoutPullback continuationLiquidity sweep + reclaim
2️⃣ Opening ReversalTime: 9:35–10:00Character:Early traders trappedCounter-move against opening spikePatterns:Gap fillSweep of opening extremeDouble top/bottom off first pushEdge Type:Reversal entry at exhaustionVWAP reversion
III. Expansion & Structure Phase (9:50 – 11:00)After opening volatility stabilizes.1️⃣ Trend Continuation WindowTime: 9:50–10:30Character:Structured pullbacksHigher lows / lower highs formingTrend clarity improvesPatterns:Ascending support compressionFlag formationsEMA/SMA pullback entriesVWAP trend holdsEdge Type:Pullback addsStructured scalingBreakout from compressionThis is often where A+ trend days form.
2️⃣ Mid-Morning Liquidity ExpansionTime: 10:00–10:30Common for:Second impulse legHigh-of-day or low-of-day formationAlgo-driven stop sweep near 00 / 25 / 50 levelsEdge Type:Acceptance breakoutLiquidity sweep continuation
IV. Late Morning Transition (11:00 – 12:00)Character:Volume dropsRange compressionRotational behavior increasesPatterns:VWAP ping-pongNarrow range coilFalse breakoutsChop around round numbersEdge Type:Mean reversionSmall scalpsAvoid large scaling
V. Midday / Lunch Session (12:00 – 1:30)Character:Lowest liquidity of the dayAlgorithmic micro-rotationsNo strong initiative order flowPatterns:Tight rangesStop hunts around small intraday levelsSlow grind channelsEdge Type:PatienceLight size onlyAvoid scaling aggressivelyMost large traders reduce size here.
VI. Early Afternoon Repricing (1:30 – 2:30)Liquidity starts returning.1️⃣ Early Afternoon PushTime: 1:30–2:00Character:Repricing toward morning extremesTest of VWAP or daily high/lowPatterns:Trend resumptionRange breakoutFailed breakdown/breakout
2️⃣ Power Hour Initiation (2:00 – 2:30)Often begins directional bias.Patterns:Break of morning rangeGamma-driven movesStrong acceptance beyond key levelsEdge Type:Momentum re-entryStructured adds
VII. Power Hour (2:30 – 3:45)High-probability expansion window.Character:Institutional positioningHedging flowsTrend acceleration or reversalPatterns:Late-day trend continuationSqueeze movesVWAP reclaim + expansionClose imbalance setupEdge Type:Aggressive scalingHold runnersBreakout continuation
VIII. Closing Auction (3:45 – 4:00)Character:Imbalance-driven volatilityFast directional burstsLarge closing printsPatterns:Final squeezeReversal flushClose-only imbalance moveEdge Type:Fast scalpsNot ideal for large new swing entries
Summary View of the Trading DayPhaseTimeBehaviorBest Strategy TypePre-Market6:00–9:29Range / prepMean reversionOpening Drive9:30–9:50ImbalanceMomentumExpansion9:50–11:00Structured trendPullback scalingLate Morning11:00–12:00RotationLight scalpsLunch12:00–1:30CompressionAvoid sizeEarly Afternoon1:30–2:30RepricingBreakoutsPower Hour2:30–3:45ExpansionAggressive scalingClose3:45–4:00ImbalanceFast trades
If you’d like next, I can:Map each time segment to A+/A/B trade grading.Explain which periods statistically support 80–100 contract scaling.Or show how to program ODMAR2 to adjust behavior based on time-of-day regime.

To the author, Javier ...

Thank you for “The Power 100.” I'm honored to be mentioned along other great authors, advocates, and pioneers that paved the way and continue to contribute to an amazing and unique industry. Congratulations to everyone mentioned and those who continue to make progress for communities and patients This piece reflects integrity, context, and respect for the architects of this movement.

- Dr. Newton

MEDICAL CANNABIS STUDIES & AWARENESS MONTHS

Here are some 2025-2026 medical cannabis studies you may find interesting

1. April 2025: Global Consensus on Oncological Pain

Study: Meta-analysis of medical cannabis outcomes and associations with cancer
Numbers: Meta-analysis of hundreds of studies (sentiment analysis of over 2,500 data points).
Ratio & Route: Multi-modal analysis; prioritized oral and sublingual routes for maintenance and vaporization for acute breakthrough pain.
Results: Found clinical support for medical cannabis in cancer care is 31.38x stronger than opposition.
URL: https://pubmed.ncbi.nlm.nih.gov/40303989/

2. May 2025: Breakthrough in Seizure Freedom

Study: 19 patients report seizure freedom with medical cannabis oil treatment
Numbers: 19 patients (15 pediatric, 4 adult) with drug-resistant epilepsy.
Ratio & Route: Full-spectrum CBD-rich oils (typically 20:1 to 25:1 CBD:THC) administered sublingually/orally.
Results: Median of 245 days of total seizure freedom; 3 patients successfully weaned off all other anti-seizure medications.
URL: https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1570531/full

3. June 2025: Florida State Registry (CCORC) Annual Findings

Study: Proceedings of the 2025 Cannabis Clinical Outcomes Research Conference
Numbers: Registry-level data from 930,000+ active Florida patients.
Ratio & Route: Diverse Florida-specific routes including flower (inhalation) and low-THC oils (oral).
Results: Significant statewide reduction in opioid prescriptions; established high safety profile for Florida's geriatric demographic.
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12823107/

4. July 2025: Hospitalization Rates and Quality of Life

Study: Medical Cannabis Use and Healthcare Utilization Among Patients with Chronic Pain
Numbers: Causal inference study using data from a multi-state certifying body (Leafwell).
Ratio & Route: Various dispensary-grade products used over a 12-month period.
Results: 3.2% reduction in ER visits and 2.0% reduction in urgent care visits; fewer "unhealthy days" per month reported.
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12286269/

5. August 2025: Same-Day PTSD Relief for Veterans

Study: Daily Associations Between Cannabis Use and PTSD Symptoms in Military Veterans
Numbers: 74 military veterans with service-connected PTSD.
Ratio & Route: Ad-libitum (self-managed) use; typically high-THC flower or 1:1 ratios.
Results: Same-day cannabis use significantly lowered symptom severity and "negative affect" spikes.
URL: https://www.sciencedirect.com/science/article/abs/pii/S0165178125002744, and https://www.marijuanamoment.net/using-marijuana-helps-military-veterans-experience-lower-ptsd-symptoms-on-days-they-use-it-federally-funded-study-shows/

6. September 2025: Opioid-Sparing Synergy

Study: CMCR Investigators' Meeting: Opioid-sparing Effects of Cannabinoids
Numbers: Preclinical and preliminary clinical patient data.
Ratio & Route: CBD vapor and THC:CBD combinations.
Results: Vaporized CBD decreased opioid intake without the reinforcing "reward" behavior found in high-THC products.
URL: https://www.cmcr.ucsd.edu/index.php/news-2/homeblog/464-cmcr-investigators-meeting-september-2025

7. October 2025: Alzheimer's Disease Microdosing

Study: A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease
Numbers: Phase 2 trial of elderly patients (ages 60–80).
Ratio & Route: 1.4:1 THC:CBD oral extract; micro-dose of 0.35mg THC / 0.24mg CBD daily.
Results: Significantly higher MMSE (cognitive) scores at 26 weeks compared to placebo group.
URL: https://pubmed.ncbi.nlm.nih.gov/41160460/

8. December 2025: Sustained Opioid Reduction (JAMA)

Study: Medical cannabis and opioid receipt among adults with chronic pain
Numbers: 204 participants tracked prospectively for 18 months.
Ratio & Route: Clinician-certified medical cannabis via oral, sublingual, and inhaled routes.
Results: 22% reduction in daily opioid MME; a 30-day cannabis supply was linked to 3.53 fewer MME per day.
URL: https://pubmed.ncbi.nlm.nih.gov/41359313/

9. January 2026: Early Integration for Pancreatic Cancer

Study: Pilot Randomized Trial of Medical Cannabis (CanPan)
Numbers: 34 patients with advanced pancreatic cancer.
Ratio & Route: Standard-of-care cannabis (patient's choice); median dose of 7.3 mg THC daily.
Results: 70% improvement in sleep and 44% improvement in pain; early access yielded better outcomes than delayed access.
URL: https://ascopubs.org/doi/abs/10.1200/OP-25-01165

10. January 2026: Endometriosis and Quality of Life

Study: Cannabis Formulations Associated With Reduced Pain in Endometriosis Patients
Numbers: 28 patients (New Zealand cohort) and 63 patients (UK Medical Cannabis Registry).
Ratio & Route: CBD-dominant oils or balanced THC:CBD flower/oil.
Results: Significant drop in "worst pain" (from 7.62 to 5.38) and massive improvement in EHP-30 health scores.
URL: https://norml.org/news/2026/01/29/study-cannabis-formulations-associated-with-reduced-pain-improved-quality-of-life-in-endometriosis-patients/

Here are some of the Medical Awareness Months related to Florida MMJ Qualified Conditions

January

Glaucoma
Organizations: Glaucoma Research Foundation; American Academy of Ophthalmology

February

General wellness, mobility, chronic pain (adaptive sports education)
' Roll-up' initiative to sport adaptive sports athletes

March

Multiple sclerosis; colorectal cancer; traumatic brain injury; spasticity; neuropathic pain
Organizations: National Multiple Sclerosis Society; Colorectal Cancer Alliance

April

Parkinson’s disease; autism spectrum disorder (symptom-based)
Organizations: Parkinson’s Foundation; Michael J. Fox Foundation; Neuro Challenge Foundation

May

Arthritis; fibromyalgia; chronic musculoskeletal pain; senior health
Organizations: Arthritis Foundation; Administration for Community Living

June

PTSD; anxiety disorders; migraine
Organizations: National Center for PTSD; American Migraine Foundation

July

General seizure education; chronic pain (7/10 oil-education anchor only)
Organizations: Americans for Safe Access

August

Crohn’s disease; inflammatory bowel disease; GI disorders; nausea; appetite loss
Organizations: Crohn’s & Colitis Foundation; International Foundation for Gastrointestinal Disorders

September

Prostate cancer; chronic pain; neuropathy
Organizations: Prostate Cancer Foundation; U.S. Pain Foundation

October

Breast cancer; cancer supportive care; chemotherapy-induced nausea; neuropathy
Organizations: Susan G. Komen; American Cancer Society

November

Epilepsy / seizure disorders; lung cancer; hospice & palliative care; terminal illness
Organizations: Epilepsy Foundation; National Hospice and Palliative Care Organization

December

HIV/AIDS; cachexia; chronic pain; sleep disturbance
Organizations: Centers for Disease Control and Prevention; HIV.gov
Key date: December 1 – World AIDS Day

Let me know if you have any questions about any of these studies, other research or the awareness months.

Dr Newton

EVENTS CALENDAR

MARCH

Sat 21 ATL (NAACP) Health Panel

Fri 27-30 S. Florida

APRIL

Fri 3 Tampa (WTOs)

ATL Cannabase

Sun ORL CarsnCoffee - 2nd Sunday.

MAY

End FMCCE

JUNE

JULY

11th SAT NEWTONVILLE, NJ.

===

Here’s the class schedule:

Monday & Wednesday | 8–9 PM ET – Post Market Analysis

Tuesday & Thursday | 9:30–10 AM ET – Live Market Performance (Recording available)

Jax - 3/6, [3/13=Mbeo], 3/20 , 3/27 (Telehealth 10am), 4/3, 4/24

HEALTH AWARENESS MONTHS

JAN — Cervical Cancer / Thyroid / Glaucoma / Migraine

Cervical CA: 600 K global │ 13 K US yearly. CBD + curcumin reduce inflammation; folate, zinc, and AHCC boost immunity and HPV clearance.
Thyroid: 200 M global │ 20 M US. CBD stabilizes hormones; iodine + selenium support metabolism and stress resilience.
Glaucoma: 80 M global │ 3 M US. THC lowers eye pressure; omega-3 + laser protect vision.
Migraine: MOVED TO JUNE

FEB — Heart Disease / Cancer / PTSD / Fibromyalgia

Heart: 550 M global │ 697 K US deaths yearly. CBD + omega-3 lower BP; CoQ10 + turmeric improve vascular tone.
Cancer: 20 M global │ 1.9 M US. THC/CBD ease chemo pain; IV vit C + hyperthermia improve recovery.
PTSD: 350 M global │ 13 M US. CBN + ketamine calm fear circuitry; EMDR builds resilience.
Fibromyalgia: 100 M global. CBD, 5-HTP, and magnesium improve sleep and reduce central sensitization.

MAR — Brain Injury / Colorectal CA / MS / Anxiety

TBI: 69 M global │ 1.5 M US. CBD + omega-3 repair neurons; ketamine + rehab enhance neuroplasticity.
CRC: 1.9 M global │ 150 K US. Curcumin + fiber reduce tumor growth; cannabis eases abdominal pain.
MS: 2.8 M global. CBD/THC mix reduces spasticity; vitamin D + B12 enhance myelin repair.
Anxiety: 301 M global │ 42 M US. CBD + mindfulness reduce cortisol; adaptogens like ashwagandha stabilize mood.

APR — Autism / Alcohol Abuse / Epilepsy / Financial Stress

Autism: 75 M global │ 1 in 36 US kids. CBD eases anxiety; B6 + magnesium aid cognition.
Alcohol use: 283 M global │ 140 K US deaths. IV B-complex detox + cannabis reduce cravings.
Epilepsy: MOVED TO NOVEMBER
Financial anxiety: 200 M global. Budget therapy + journaling reduce pain flare frequency and insomnia.

MAY — Mental Health / Arthritis / Back Pain / Burnout

Depression: 300 M global │ 21 M US. Ketamine + omega-3 elevate mood; magnesium + CBD aid serotonin.
Arthritis: 350 M global │ 53 M US. PRP + CBG relieve joints; curcumin + collagen rebuild cartilage.
Back Pain: 619 M global │ 65 M US. CBD + epidural steroids relieve inflammation; posture therapy prevents relapse.
Burnout: 400 M global. Adaptogens + mindfulness + B12 restore energy.

JUN — Men's Health / MIGRAINE / ED / Sleep

Prostate: 1.4 M global │ 288 K US. Saw palmetto + zinc improve flow; CBD + low-dose THC reduce pain.
Migraine: 1 B global │ 39 M US. Botox + CBD block pain; magnesium + riboflavin reduce triggers.
ED: 320 M global. PRP + shockwave restore circulation; L-arginine boosts nitric oxide.
Insomnia: 1 B global │ 70 M US. CBN + melatonin restore REM; magnesium glycinate calms nerves.

JUL — Minority Mental Health / Skin Cancer / PTSD / Burnout

PTSD: 350 M global │ 13 M US. Ketamine infusions reset trauma pathways; CBN + CBD aid rest.
Skin Cancer: 1 M global │ 5.5 M US. Topical CBD + vitamin D reduce UV-induced DNA damage.
Burnout: 400 M global. Omega-3, mindfulness, and social support prevent physician fatigue.

AUG — Immunization / Psoriasis / Autoimmune / Chronic Fatigue

Psoriasis: 125 M global │ 7.5 M US. CBD + turmeric calm inflammation; UVB phototherapy enhances skin renewal.
Lupus: 5 M global │ 200 K US. Omega-3 + CBD lower flares; vitamin D + CoQ10 aid immunity.
Chronic Fatigue: 150 M global. NAD+ IVs + adaptogens restore mitochondrial energy.

SEP — Chronic Pain / Prostate CA / Neuropathy / Addiction

Chronic Pain: 1.5 B global │ 50 M US. THC/CBD ↓ opioid need > 60%; nerve blocks + acupuncture improve function.
Prostate CA: 1.4 M global │ 288 K US. CBD reduces bone pain; lycopene + vit D support prevention.
Neuropathy: 240 M global. Alpha-lipoic acid + CBG + IV B12 repair nerves.
Addiction: 200 M global. Cannabis + ketamine-assisted therapy improve long-term recovery.

OCT — Breast CA / Depression / Osteoporosis / Financial Toxicity

Breast CA: 2.3 M global │ 300 K US. CBD + CBG relieve chemo pain; omega-3 aid tissue repair.
Depression: 300 M global │ 21 M US. Ketamine + 5-HTP lift mood; mindfulness builds resilience.
Osteoporosis: 500 M global │ 10 M US. PRP + vitamin K2 + weight training increase bone density.
Financial toxicity: 80% cancer patients affected — budgeting + advocacy reduce distress.

NOV — Lung CA / Diabetes / COPD / EPILEPSY / Pain Crisis

Lung CA: 2.2 M global │ 234 K US. CBD + vit C IV reduce fatigue; THC aids appetite and mood.
Diabetes: 540 M global │ 38 M US. CBG + berberine enhance glucose control; magnesium supports insulin.
COPD: 390 M global │ 16 M US. Nebulized CBD + breathing rehab improve oxygenation.
Epilepsy: 65 M global │ 3 M US. CBD (Epidiolex) FDA-approved; ketogenic diet aids seizure control.
Pain crisis: 1.5 B global. Multimodal pain + cannabis reduce ER visits.

DEC — HIV/AIDS / Road Injury / Insomnia / Holiday Stress

HIV: 39 M global │ 1.2 M US. CBD ↑ appetite; B-complex + omega-3 boost immunity.
Traffic injury: 1.3 M global deaths │ 46 K US. Post-injury PRP + CBD ↓ opioid reliance.
Insomnia: 1 B global │ 70 M US. CBN + magnesium improve rest.
Holiday stress: Mindfulness + CBD tea ↓ cortisol; gratitude resets the brain.

AWARENESS MONTHS (Empathy & Perspective)

Aug – Immunization, Psoriasis, National Wellness, Pain-Free Posture Awareness, Musculoskeletal Health

Sep – Healthy Aging, Pain Awareness, Suicide Prevention, Cholesterol, Yoga, Fall Prevention

Oct – Emotional Wellness, Breast Cancer, Liver Awareness, Health Literacy, Ergonomics Awareness (Workplace Pain Prevention), Bone & Joint Health, First week = Mental Illness Awareness Week (NAMI), 10th - Depression Screening Day,

Nov – Alzheimer’s, Diabetes, Lung Cancer, Family Caregivers, Sleep Comfort, TMJ Awareness, Sciatica Awareness, National Family Health History Awareness

Dec – Handwashing Awareness Month, Safe Toys & Gifts

Jan – Healthy Weight, Mental Wellness, Glaucoma, Thyroid, Cervical Health, Rheumatoid Arthritis

Feb – American Heart, Cancer Prevention, Black Hx Month

Mar – Nutrition, Kidney Cancer, Colorectal Cancer, Sleep Awareness, Autoimmune Disease Awareness, TBI, MULTIPLE SCLEROSIS - NMSS

Apr – Stress Awareness, Autism Awareness, Minority Health, Parkinson’s, IBS, Injury Prevention, Joint Health

May – Mental Health, Arthritis, Stroke, Osteoporosis, Women's Health, Physical Fitness & Sports Injury Prevention, Fibromyalgia Awareness

Jun – Brain Awareness, Men's Health, PTSD, Migraine, Alzheimer’s & Dementia, National Safety Month (Injury Prevention), Spine Health Work Safety Month

Jul – Healthy Vision, UV Safety, Minority Mental Health, Chronic Disease Management, Scoliosis Awareness

========

HIPAA/Privacy:

Data Privacy Day (January 28): Highlights protecting patient information and HIPAA Privacy Rule compliance.
Health Information Professionals (HIP) Week (March/April): Honors HIM professionals and underscores HIPAA best practices.
Cybersecurity Awareness Month (October): Stresses HIPAA Security Rule adherence through cybersecurity initiatives.

Workplace Safety:

National Safety Month (June): Promotes overall workplace safety, including OSHA standards and injury prevention.
Patient Safety Awareness Week (March): Focuses on reducing errors and improving patient outcomes.
Infection Prevention Week (October): Emphasizes policies to prevent healthcare-associated infections.
Respiratory Protection Week (September): Reinforces the proper use of respirators and OSHA compliance.
Safe + Sound Week (August): Encourages implementing effective safety and health programs.
Fire Prevention Week (Week of October 9): Highlights fire safety measures and emergency evacuation plans.
[ In NC November is Raditation Safety Month ]

Favorite Places in

ATL - Bookstore Gallery, Beltline/DeKalb, Buckhead, Holy Zion Church, RICE Center, Midtown,

Tampa - Aquarium, Attorney Strickland's new office, Trulieve, USF, Ybor,

Orlando - BOT, TulipsBlooms.org, Trulieve, Disney Parks, Rosen Centre, Mall at Millenia, Dr Massi's, Dr Mbeo's, MCO, IMG, Oh Que Bueno,

Miami - Brightline, Trulieve, Gables Pain, MARC,

Jax - My office, NWM, Town Center, Libraries, Avenues Mall

' Do Every Day, All You Can Do That Day '

- Dr Newton

↑ signal + ↓ noise → success

produce energy | dream bigger | 1 project away |

"Advancing Pain Relief Through Innovation, Education, and Compassion."

Calendario privado - TerelNewton.com

Email: DrTerelNewton@gmail.com

GUEST SPEAKER: Multiple Conferences and events ...

ELEVATE ATL | BOOK STORE GALLERY

ATTENDED and/or PRESENTED...

FL - CANNABIS LAB, FSIPP, SPACE CON, SMOKEN YOGA

GA - WOMEN IN BIZ EXPO (ATL)

NEVADA - MJ BIZ CON, Blue-Ribbon Study Committee (Ga)

Dispensary Tours (Retail) = Medical Doctors/Clinic Staff, BCFCF, Tulips Blooms, Media Day, Grand Opening.

Dispensary Tours (Cultivation) = Universities, Educators/Research/Community Outreach, et al

SUPPORT ...

BOT CANNABIZIAC M4MM MMERI FMCCE FMA GMA

Disclaimer:

Information provided is for reference only and does not imply affiliation or endorsement with the mentioned individuals, companies, products, services, treatments, and websites. For informational purposes only - contact your medical provider for health and medical advice. Content accuracy, completeness, and timeliness are not guaranteed. Inclusion of information and websites does not constitute endorsement. Users should exercise caution when accessing external content. See your medical, legal, finance, tax, spiritual and other professionals for discussion, guidance, planning, recommendations and greater understanding of the risks, benefits, options and ability to apply any information to your situation.

GREAT PEOPLE TO WORK WITH ...FSU

Faculty Profiles

Dr. Nicole Ennis, Ph.D. – Associate Professor and Vice Chair, Dept. of Behavioral Sciences & Social Medicine (BSSM). Dr. Ennis is a leading behavioral scientist with a focus on public health, substance use, and medical cannabis outcomes researchmed.fsu.edu. She has extensive experience developing and implementing interventions for people with chronic illnesses (e.g. HIV) and those affected by substance misusemed.fsu.edu. Notably, Dr. Ennis and collaborators have been at the forefront of studying medical marijuana’s effects – for example, examining how long-term medical cannabis use (alone or with opioids) impacts driving performance in older adultsmed.fsu.edu. Her work in this area has earned continuous funding from the National Institute on Drug Abuse (NIDA) and other agencies for over a decademed.fsu.edu. In recognition of her expertise, FSU’s president recently nominated Dr. Ennis to the Board of the Florida Consortium for Medical Marijuana Clinical Outcomes Research, a statewide research initiativemed.fsu.edu. This speaks to her openness and leadership in medical cannabis research, as well as alignment with Florida’s health priorities. Contact: nennis@fsu.edu (Department of BSSM, FSU College of Medicine)med.fsu.edu.

Dr. Heather A. Flynn, Ph.D. – Professor and Chair, Dept. of Behavioral Sciences & Social Medicine. Dr. Flynn is a senior faculty member and clinical psychologist specializing in mental health, behavioral health integration, and health services researchmed.fsu.edu med.fsu.edu. Under her leadership, the BSSM department has secured over $21 million in external grants (2015–2019) in mission-focused areas including chronic illness, mental health, substance use/addiction, and health policymed.fsu.edu. She has a proven NIH funding track record (e.g. perinatal depression research) and is a strong advocate for patient‐centered outcomes research and community-engaged studiesmed.fsu.edu. Importantly, Dr. Flynn has demonstrated openness to medical cannabis research – she co-authored a recent study on Florida medical cannabis patients’ health outcomes and opioid use reductionmed.fsu.edu. As department chair, she can lend significant institutional support and ensure any cannabis study aligns with FSU’s values of scientific rigor and public health impact. Contact: heather.flynn@med.fsu.edu (Chair, BSSM, FSU College of Medicine)med.fsu.edu.

Dr. Laura Reid Marks, Ph.D. – Associate Professor, Dept. of Behavioral Sciences & Social Medicine. Dr. Marks is a behavioral health researcher focusing on substance use, mental health, and health disparities in emerging adultsmed.fsu.edu ctbs.fsu.edu. She directs the G.R.O.W.T.H. research lab at FSU’s Center for Translational Behavioral Science, investigating how factors like discrimination and stress influence health behaviors. Her work includes studying young adults’ alcohol and cannabis use patterns – for instance, she recently published on perceived increases in alcohol and cannabis use among diverse college-aged adults during the pandemicmed.fsu.edu. This background shows her comfort with cannabis-related research questions (especially regarding vulnerable or underserved populations). Dr. Marks’s expertise in culturally tailored interventions and digital health (mHealth) toolsmed.fsu.edu could be valuable for innovative study designs (e.g. mobile health data collection from medical marijuana patients). She would likely champion projects examining cannabis in the context of mental health and health equity, aligning with NIH’s focus on disparity populations. Contact: laura.reidmarks@fsu.edu (Dept. of BSSM, FSU College of Medicine)ctbs.fsu.edu.

Collaboration Options

Joint Observational Study (MMJ Registry + FSU Networks): A collaborative observational study leveraging MMJOutcomes.org’s patient registry data and FSU’s clinical networks. This could involve prospectively tracking health outcomes (pain levels, opioid use, functional status, etc.) in patients using medical cannabis. FSU’s statewide clinical footprint (primary care and specialty clinics, plus the geriatric patient base) provides access to diverse patient populations, including older adults and rural patients – groups of high interest as Florida’s medical cannabis usage growsmed.fsu.edu. By pooling MMJOutcomes registry data with FSU clinical data, the study can yield real-world evidence on medical cannabis efficacy and safety (e.g. improvements in pain and quality of life, reduction in opioid dosagessciencedaily.com sciencedaily.com). This aligns with Florida’s public health priorities (addressing the opioid crisis through alternative pain therapies) and would likely earn institutional approval, as it builds on existing FSU strengths in community-based research and patient-centered outcomesmed.fsu.edu.
Co-authored Grant Proposal (Cannabis in Medicaid/Vulnerable Populations): A partnership to co-write a grant proposal focusing on evaluating medical cannabis outcomes in Florida’s Medicaid or other vulnerable populations. This could be a multidisciplinary project studying how cannabis therapy affects healthcare utilization, costs, or health metrics in low-income or minority patients (for example, examining if medical cannabis use correlates with reduced emergency visits or improved chronic pain management in Medicaid recipients). Such a proposal could target NIH (e.g. NIDA or NIMHD) or state funding. It would merge Dr. Ennis’s and Dr. Marks’s expertise in substance use and health disparities with Dr. Flynn’s experience in large-scale health services research. Strategically, this aligns with NIH funding trends encouraging research on cannabis as it relates to pain and opioid reductionmed.fsu.edu, and with Florida’s interest in evidence-based cannabis policy for its most vulnerable citizens. A well-crafted grant on this topic not only addresses pressing state health questions but also leverages FSU’s emphasis on health equity and policy-relevant research.
Cross-Institution Academic Publication (Cannabis Outcomes Review): A scholarly collaboration to produce a comprehensive review or policy paper on medical cannabis outcomes, co-authored by Dr. Newton and FSU faculty for a high-impact academic journal. Possible topics include a systematic review of clinical outcomes of medical cannabis in specific conditions (e.g. chronic pain, PTSD, or in older adults), or a review of policy and public health impacts of Florida’s medical marijuana program. Co-authoring such a paper would capitalize on FSU faculty’s subject-matter knowledge – Dr. Ennis’s work on driving and safety outcomesmed.fsu.edu, Dr. Marks’s insight into young adult usage patternsmed.fsu.edu, and Dr. Flynn’s perspective on mental health outcomes – combined with MMJOutcomes data and Dr. Newton’s registry findings. This publication could serve as a cornerstone for Florida’s thought leadership in cannabis research, and is in line with FSU’s academic mission to translate research into practice and policy. It also sets the stage for future joint projects, demonstrating a united front on cannabis outcomes research that would be well-received by both the university and state consortium.

GREAT PEOPLE TO WORK WITH ...FAMU

FAMU Profiles

Dr. G. P. Mendie (MMERI Executive Director)
https://www.famu.edu/administration/research/contact-us.php

Dr. Donald E. Palm III
https://www.famu.edu/_training-and-testing/backup-archived-pages/presidential-search/pdf/cv-DonaldPalm.pdf
(Also: https://news.famu.edu/2025/famu-coo-donald-palm-selected-for-news-service-of-florida-50-over-50-list.php)

Dr. Charles A. Weatherford
https://www.famu.edu/info/faculty-staff/profiles/cst/charles-weatherford.php

Dr. Mandip S. Sachdeva
https://pharmacy.famu.edu/research/research_laboratories/sachdeva-laboratory/index.php

Dr. Otis W. Kirksey
https://www.floridahealth.gov/provider-and-partner-resources/research/florida-health-grand-rounds/Bio-DrKirksey020821.pdf
(Also: https://events.diabetes.org/b/sp/otis-kirksey-1080

Dr. G.P. Mendie

Official Profile: Executive Director of FAMU’s Medical Marijuana Education and Research Initiative (MMERI), listed on FAMU’s Division of Research contact pagefamu.edu. (This page provides his name, title, and email as the MMERI Executive Director.)
Official Image: A professional headshot is available via FAMU’s Service Excellence “Gallery of Distinction” (he was recognized as an Employee of the Quarter)famu.edu. Direct image URL: 640x480_G.P.-Mendie.jpg on FAMU’s site (the photo is embedded on the gallery page, but users can view/download it by accessing the image link).

Dr. Donald E. Palm

Official Profile: Executive Vice President and Chief Operating Officer (COO) of FAMU. (No dedicated faculty profile page is published; however, FAMU’s news release announcing his recognition as a “50 Over 50” honoree serves as an official bionews.famu.edu.) This news article outlines Dr. Palm’s role and background at FAMU.
Official Image: A formal headshot of Dr. Palm is embedded in the FAMU News articlenews.famu.edu. Direct image URL: 1024x768_donald-palm.jpg on the FAMU News site (the image appears in the news story and can be saved from the page).

Dr. Charles Weatherford

Official Profile: Vice President for Research at FAMU, and Professor of Physics. His official faculty profile page on FAMU’s website provides his biography and credentialsfamu.edu famu.edu. (This profile notes his roles, education, and accomplishments in research and academia at FAMU.)
Official Image: The profile includes an official headshot of Dr. Weatherfordfamu.edu. Direct image URL: 450x450_Dr.-Weatherford.jpg on the FAMU site (this is the image displayed on his faculty profile, which can be viewed or downloaded directly).

Dr. Mandip S. Sachdeva

Official Profile: Professor of Pharmaceutical Sciences in the FAMU College of Pharmacy and Pharmaceutical Sciences (CoPPS). An official page on the CoPPS research site (Sachdeva Lab page) features his Biosketch and qualificationspharmacy.famu.edu. (This lab profile highlights his education, positions, and research focus at FAMU.)
Official Image: Dr. Sachdeva’s headshot is included in the CoPPS faculty/staff directorypharmacy.famu.edu. Direct image URL: Mandip-Sachdeva.jpg on the pharmacy.famu.edu server (the photo is shown in the directory listing and can be downloaded by accessing the image link).

Dr. Otis W. Kirksey

Official Profile: N/A on FAMU site. Dr. Kirksey is a retired FAMU pharmacy faculty member (honored in 2020 as Professor Emeritus of Pharmacy Practice)floridahealth.gov. There is no current faculty profile on FAMU’s websites due to his retirement. (His contributions are noted in external publications, but no active FAMU page exists for him.)
Official Image: Not available. No official image or headshot is posted on FAMU’s current sites for Dr. Kirksey (as a retired faculty, he is not featured on current directories). Any photos of Dr. Kirksey appear on external sites (e.g. American Diabetes Association profiles), not on FAMU-hosted pages.

Vocab List - 1st 50

Monday & Wednesday | 8–9 PM ET – Post Market Analysis
Tuesday & Thursday | 9:30–10 AM ET – Live Market Performance

Absorption Passive limit orders neutralize aggressive orders, stopping continuation and signaling reversal.
ATR (Average True Range) Measures volatility and sets dynamic stop distances.
Bearish Engulfing Large red candle overtakes a smaller green one, signaling reversal.
Bid Stack Visible buy liquidity showing potential support depth.
Breakout Strong move above resistance with volume confirming trend ignition.
Breakdown Strong move below support triggering stops and continuation.
Compression Tight price clustering before explosive expansion.
Consolidation Sideways balance where buyers and sellers neutralize each other.
Continuation Trend resumes after pullback, confirming strong directional pressure.
Cumulative Delta Net aggressive buying vs selling revealing hidden positioning.
Demand Zone Area of prior institutional buying producing future bounces.
Delta Imbalance Heavy skew between buy and sell volume predicting directional moves.
Doji Indecision candle with equal open and close signaling potential shift.
Downtrend Sequence of lower highs and lower lows showing bearish control.
EMA (Exponential Moving Average) Fast-moving average defining short-term trend direction.
Engulfing Pattern Candle overtakes previous candle’s range signaling momentum takeover.
Expansion Volatility widening after compression, enabling strong trend legs.
Fair Value Gap (FVG) Inefficiency zone often retraced for balance.
Fib Retracement Key pullback levels (38.2, 50, 61.8) used for trend entries.
Fib Target Zone Common profit zones (100%, 127%, 161.8%).
First Pullback Entry High-probability early-trend entry after initial push.
Footprint Chart Displays bid–ask volume inside candles to expose imbalance.
Hammer Bullish reversal candle showing strong rejection of lows.
Hanging Man Bearish reversal candle after an uptrend with long lower wick.
Higher High New swing high confirming bullish structure.
Higher Low Rising trough confirming buyers stepping in earlier.
Imbalance Aggressive displacement leaving inefficient price areas later filled.
Impulse Leg Strong directional move used for Fib anchoring.
Inside Bar Candle fully inside previous bar signaling contraction.
Liquidity Grab Stop-triggering sweep beyond a key level before reversal.
Limit Order Passive order resting at a specific price.
MACD Momentum indicator showing trend acceleration or reversal.
Market Order Immediate execution consuming liquidity, indicating urgency.
Micro Pullback Very shallow retracement during strong trends showing dominance.
NQ/ES Futures Basics Highly liquid index futures used for intraday trend trading.
Order Block Institutional footprint of accumulation or distribution.
POC (Point of Control) Highest volume price acting as magnet and pivot.
Price Discovery Auction process establishing fair value.
Range Expansion Break from tight structure into larger price moves.
Range Contraction Tightening volatility showing indecision before move.
Rejection Wick Long wick showing strong denial of price continuation.
Reversal Trend turning after exhaustion and structural break.
RSI Momentum oscillator identifying overbought/oversold or divergence.
Scalping Framework Fast execution system targeting small high-frequency gains.
Slippage Worse-than-expected fill due to volatility or thin liquidity.
Stop Run Targeting of stop clusters to create volatility and fill liquidity.
Structure Break Major swing break confirming trend shift.
Supply Zone Region of previous institutional selling causing future resistance.
Support Price area where demand stops decline.

VWAP Volume-weighted fair value used for mean reversion and trend strength.

Advanced

I. Master Alphabetical Glossary (High-Capital Scalping)

AAR – Aggressive Add Reclaim
Reclaim of key liquidity level after sweep with immediate displacement and confirming order flow, allowing confident size increase.
Example: Sweep PDL, reclaim with impulse + delta surge → add 30c.

ABR – Algo Break & Run
Algorithm-driven breakout with rapid expansion, minimal pullback, sustained velocity beyond structure.
Example: ORB break, stacked prints, 60-point run in two minutes.

AON – All-or-None Execution
Full-size order must fill entirely or not at all, preventing fragmented execution in thin liquidity.
Example: 75c AON above range high during expansion setup.

ATRX – ATR Expansion Event
Current range exceeds recent ATR average, signaling volatility expansion and institutional participation.
Example: 1m candle doubles 14ATR during VWAP break.

BDS – Bid Stack Absorption
Large resting bids absorb aggressive sellers, often preceding upside reversal or continuation.
Example: Repeated hits into bid at VWAP, price holds firm.

BRR – Break-Retest-Run
Break level, controlled pullback, renewed expansion confirming continuation.
Example: Break PDH → shallow pullback → bullish engulfing → scale 50c.

CBR – Continuation Breakout Re-entry
Secondary entry after breakout when pullback holds structure and momentum resumes.
Example: Pullback to breakout level with strong CLV → re-enter.

CD – Cumulative Delta
Running total of aggressive buying versus selling; confirms imbalance or divergence.
Example: Price flat, delta rising → bullish breakout pending.

CLV – Closing Location Value
Where candle closes within range; high close signals directional conviction.
Example: Marubozu close at high → continuation bias.

DLR – Deep Liquidity Raid
Stop sweep beyond obvious highs/lows before reversal or acceleration.
Example: Spike above ONH, immediate rejection wick.

DVP – Delta Volume Pulse
Sudden surge in aggressive order flow confirming expansion.
Example: +5,000 delta spike on breakout candle.

ELR – Extreme Liquidity Reversal
High-velocity reversal immediately after liquidity sweep.
Example: Stop purge above PDH → 80-point bearish impulse.

FBO – Failed Breakout
Break lacking follow-through, leading to sharp opposite move.
Example: Break high stalls, inside bar forms → short trigger.

FLS – First Liquidity Sweep
Initial stop run before structural move develops.
Example: Sweep range low, reclaim, build long.

HTF-A – Higher Timeframe Alignment
Lower timeframe entries aligned with 5m/15m/hourly structure bias.
Example: 1m breakout long with 15m bullish trend.

IMP – Impulse Leg
Strong directional displacement with minimal overlap, large bodies, strong volume.
Example: Three consecutive Marubozu, 100-point YM move.

LQZ – Liquidity Zone
Area containing clustered stops, equal highs/lows, visible resting liquidity.
Example: Equal highs above range attract breakout sweep.

LRR – Liquidity Reclaim & Run
Reclaim after sweep with sustained acceptance above/below level.
Example: Sweep PDL, reclaim VWAP, hold → expansion.

MEX – Momentum Exhaustion
Velocity decreases, wicks expand, delta diverges; trend fatigue signals exit.
Example: Higher highs with weakening volume.

MSS-X – Market Structure Shift with Expansion
Break in prior swing structure confirmed by displacement candle.
Example: Lower high breaks with volume expansion → trend shift.

OFI – Order Flow Imbalance
Significant disparity between aggressive buyers and sellers.
Example: 4:1 buy imbalance during breakout.

PVA – Price-Volume Acceleration
Simultaneous increase in price velocity and traded volume.
Example: Rapid 30-point move with doubled volume.

RLP – Reversal Liquidity Pocket
Tight consolidation after stop purge before reversal expansion.
Example: 3-candle base forms after sweep → long trigger.

SFA – Size Flow Acceleration
Increase in large-lot transactions supporting move.
Example: Block trades repeatedly lifting offer.

SPR – Stop-Purge Reversal
Aggressive stop sweep followed by immediate opposite expansion.
Example: Flush below range → bullish engulfing reversal.

TFX – Timeframe Expansion
Higher timeframe breakout aligns with lower timeframe trigger.
Example: 1m break aligns with 15m range break.

VEX – Volatility Expansion
Compression transitions into high-range breakout.
Example: Three narrow candles → explosive expansion bar.

VW-Dev – VWAP Deviation Extension
Significant stretch beyond VWAP deviation bands signaling continuation or exhaustion.
Example: +2 SD extension with divergence.

II. $50K+ Structured Execution Model (YM/NQ)

Capital Assumption

$50,000 account
Aggressive sizing model: 20–100 contracts (YM or NQ)
Target: 80–200+ points in expansion phase

Phase 1: Pre-Trade Qualification (All Must Align)

HTF-A + TFX present
Liquidity event confirmed (FLS / DLR / LQZ interaction)
IMP or ATRX triggered
OFI + DVP confirmation
CLV strong in breakout direction

If 4/5 present → proceed.

Phase 2: Entry Protocol

Primary triggers:
• BRR
• MSS-X
• ABR

Execution:
Initial entry 25c
Add via AAR or CBR
Scale to 50c–100c only during VEX + SFA conditions

Phase 3: Risk Architecture

Initial stop: below structural reclaim (not fixed tick)
Max per-trade risk: 3–5% capital during expansion phase
Move to BE+ only after second impulse confirmation

Phase 4: Profit Model

YM example:
100 contracts × 100 points = 10,000 points
$5 per point = $50,000

NQ example:
50 contracts × 100 points
$20 per point = $100,000

Scaling logic:
Partial at 1R
Trail via TS under impulse lows
Final exit on MEX or VW-Dev divergence

Phase 5: Exit Triggers

• MEX
• Delta divergence
• Failure to hold reclaim
• Opposing SPR

• A TERELS-integrated version
• Or a statistical probability model for $50K setups

Page updated

Google Sites

Report abuse